SCHEMBL8367145

SCHEMBL8367145

CN(C[C@H]1COC(C)(C)O1)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.39
ASGR1 P07306 1/20 0.36
HCRTR2 O43614 1/20 0.34
TMEM97 Q5BJF2 2/20 0.33
SIGMAR1 Q99720 2/20 0.33
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
DGAT1 O75907 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
USP30 Q70CQ3 1/20 0.32
FPR2 P25090 1/20 0.31
SCN9A Q15858 1/20 0.31
CHRM2 P08172 3/20 0.30
CHRM4 P08173 3/20 0.30
CHRM5 P08912 3/20 0.30
CHRM1 P11229 3/20 0.30
CHRM3 P20309 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1760428 0.84 CA2 (0.41) CA2ASGR1HCRTR2TMEM97SIGMAR1
SCHEMBL1760347 0.84 CA2 (0.41) CA2ASGR1HCRTR2TMEM97SIGMAR1
SCHEMBL1760431 0.84 CA2 (0.41) CA2ASGR1HCRTR2TMEM97SIGMAR1
SCHEMBL1022363 0.80 ALDH1A1 (0.38) ASGR1HCRTR2ALDH1A1FPR2
SCHEMBL1022362 0.80 ALDH1A1 (0.38) ASGR1HCRTR2ALDH1A1FPR2
SCHEMBL9523662 0.79 HTR1A (0.37) ASGR1ADRA1AADRA1B
SCHEMBL2238201 0.76 SLC6A4 (0.36) CHRM3
SCHEMBL3194829 0.75 CA2 (0.39) CA2TMEM97SIGMAR1ALDH1A1NPSR1
SCHEMBL13521525 0.74 HSD11B1 (0.33) CA2HCRTR2TMEM97SIGMAR1
SCHEMBL8185362 0.74 HDAC6 (0.35) CA2ASGR1HCRTR2TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096942-A1 Substituted Hydroxyethylamines ELAN PHARMACEUTICALS, INC. 2008-04-24 US disclosed
WO-2003050073-A1 SUBSTITUTED HYDROXYETHYLAMINES ELAN PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096942-A1 Substituted Hydroxyethylamines BACE1, BACE2, MME CA2 3235/4885ASGR1 1065/4885HCRTR2 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.